65,437 trials
Alzheimer's Disease · Central Nervous System Diseases
Primary: Safety and Tolerability of Multiple Doses of EVP-6124 or Placebo in Subjects With Alzheimer's Disease — 0; 0; 0; 0 Participants
Influenza
Primary: Number of Participants With Local and Systemic Immediate Reactogenicity Complaints — 0; 0; 0; 0 Participants
Healthy
Primary: Percentage of Participants Reporting Fever, Defined as Oral Temperature ≥ 101°F — 0.4; 0.0 Percentage of participants
Breast Cancer
Primary: Number of Participants With Tumor Response — 5; 9; 1; 3 participants
Multiple Myeloma · Non-Hodgkin's Lymphoma
Primary: Area Under the Plasma Concentration-time Curve (AUC) 0-72 Hours — 123; 170; 215 ng*h/mL
Schizophrenia · Schizoaffective Disorder
Primary: Presence of a Cortical (C) Type of Cataractogenic Potential Events in Participants as Assessed and Agreed by 2 Independent, Treatment-masked Ophthalmologists Using the…
Polycystic Ovary Syndrome
Primary: Reduction in Abdominal Fat as Measured by Waist Circumference. — -3.9; -1.4 cm
Active Lifestyle Males · Inactive Lifestyle Males
Primary: Energy Intake at the Meal (Exercise Session) — 1105.6; 934.8 kilocalories
Anemia · Secondary Hyperparathyroidism
Primary: Number of Participants With a Mean Intact Parathyroid Hormone Value Between 150 and 300 pg/mL and a Calcium - Phosphorus Product Value < 55 mg^2/dL^2 — 30 Participants
Epilepsy
Primary: Number of Subjects Who Experienced at Least 1 Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years) — 126 number of subjects
Myocardial Infarction
Primary: Core Study: Change From Baseline in Left Ventricular End Systolic Volume (LVESV) as Measured by Echocardiography at End of Study. — -3.14; -4.13 mL
Proliferative Diabetic Retinopathy · Diabetic Macular Edema
Primary: Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks — -4; 1; 2 Letter Score — p=<.001
Healthy
Primary: Number of Participants Reporting Fever, Defined as Oral Temperature ≥ 101°F — 1; 1 participants
Venous Thromboembolism
Primary: Average Subcutaneous Anti-Xa Blood Levels — 1.43 IU/mL
Diabetic Retinopathy · Diabetic Macular Edema
Primary: Mean Change in Visual Acuity (Letters) From Baseline to 1 Year Adjusted for Baseline Visual Acuity — 3; 9; 9; 4 Letters — p=<0.001